Drug intelligence / Profile preview

SB732462

Development stage: Unknown
Lead developer: GSK
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SB732462 is an investigational therapeutic HIV vaccine developed by GSK. It was evaluated in Phase 1 clinical trials to assess safety, reactogenicity, and immunogenicity in HIV-infected individuals, including those on highly active antiretroviral therapy (HAART) and treatment-naïve subjects. The vaccine is an adjuvanted formulation administered via intramuscular injection. It was part of GSK's efforts to develop an immunotherapy that could potentially control viral replication or enhance the immune response against HIV-1. While specific antigen details are not widely publicized in early trial documentation, it was part of a broader program investigating recombinant protein-based vaccines combined with proprietary adjuvant systems.

Other names: HIV Vaccine 732462

Beyond the preview

Go deeper on SB732462.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SB732462.

Explore the full profile